The MarketReader Minute
π Humacyte Inc's Stock Soars on FDA Milestone; Moderna's Vaccine Approval Boosts Market Sentiment | Biotech Sector Insights
Humacyte Inc's stock surged after receiving the FDA's RMAT designation for their Acellular Tissue Engineered Vessel (ATEV) in advanced peripheral artery disease. Biogen Inc's recent price movement may be related to ongoing class action lawsuits alleging securities fraud, and misleading statements.